X

Trial Profile

A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine (LEBEN) in Relapsed and Primary Refractory Hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Lenalidomide (Primary)
Indications Hodgkin's disease
Focus Adverse reactions; Therapeutic Use
Acronyms LEBEN; LEBEN-HL

Most Recent Events

08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
10 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
10 Mar 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-002810-35).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com